Curetis AG, a German developer of diagnostics, raised an additional 9.6 million euros ($13.3 million) from investors to fund human tests of a system to identify infectious diseases. Forbion Capital Partners, a Dutch venture capital firm, led the expansion of the company’s Series A financing round, which now totals 34.1 million euros, with total capital raised to date of 36.6 million euros, the Holzgerlingen-based company said today in a statement on its website. Holger Reithinger, a partner at Forbion, will have a place on Curetis’s board.
